Ireland
--:--IST
Latest
Clinical Trials in Israel / NCT05918263
Recruiting Not applicable

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

NCT05918263 · tracked via the Priya Life Science Israel tracker
Phase
Not applicable
Started
2024-01-01
Last updated
2026-07-15

Condition(s) studied

Prostate CancerProstatic Neoplasms

Investigational drug(s) / intervention(s)

High-Intensity Interval Training Exercise ProgramHigh-Intensity Interval Training Exercise Program

High-Intensity Interval Training Exercise Program: Home-based, virtually supervised, aerobic exercise program of 36 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.

High-Intensity Interval Training Exercise Program: (Optionally) Home-based, virtually supervised, aerobic exercise program of 36 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.

Study summary

The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-risk of progression undergoing active surveillance.

The name of the study intervention involved in this study is:

Aerobic high-intensity interval training (HIIT) (training exercise intervention)

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years. * Histologically diagnosed with localized prostate cancer. * Initiating or undergoing active surveillance. * Having a higher risk of progression, defined as meeting one or more of the following: (1) favorable- intermediate risk prostate tumor at diagnosis, (2) obesity (body mass index ≥ 30), and/or (3) self- identified as Black or African American. * No plans for invasive treatment for their prostate cancer in the 12 weeks following the time of enrollment. * Ability to understand and willingness to provide informed consent. Exclusion Criteria: * Received any invasive curative-intent treatment for prostate cancer, including surgery, chemotherapy, radiation therapy, and hormonal therapy. * Patients with metastasis and/or other active malignancies (except basal cell carcinoma) and/or receiving treatment for those malignancies. * Participating in any (\>0 min/week) high-intensity exercise at the time of recruitment. * Having chronic medical conditions that are clinically unstable or uncontrolled with medications, deemed high-risk for exercise. These include but are not limited to unstable cardiac diseases, uncontrolled diabetes, and bone metastases with imminent risk of fracture. * Having a high risk for noncompliance with study procedures. This will be determined by the study team based on the history of missed oncology appointments (i.e., ≥3 no-shows in 6 months) and poor responsiveness during recruitment (i.e., ≥3 unreturned contacts). * Patients who are non-English speaking and unable to complete the participant surveys.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Beth Israel Deaconess Medical Center Boston Massachusetts Completed
Brigham and Women's Hospital Boston Massachusetts Completed
Dana-Farber Cancer Institute Boston Massachusetts Completed
Fred Hutch/University of Washington Cancer Consortium Seattle Washington Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05918263 on ClinicalTrials.gov ↗ ← All trials in Israel